Ozempic-linked wrongful death suit cites GI complications: Is this a rare event or underrecognized risk?
Industry Buzz
There are many, many instances of individuals being hospitalized, having severe issues with their gastrointestinal tract, bowel blockages and things of that nature.
—Jonathan Orent, attorney
A wrongful-death lawsuit tied to semaglutide is highlighting the severe gastrointestinal complications associated with GLP-1s, after a 76-year-old woman allegedly died following prolonged vomiting and aspiration linked to gastroparesis. []
The patient, Marsha Ettinghoff, had been taking Ozempic for approximately 6 months before developing persistent nausea and vomiting that escalated over several days. Initially, her family suspected food poisoning; she later experienced regurgitation and respiratory distress. En route to the hospital, she aspirated on her vomit and died, according to news reports. []
Her family filed suit against Novo Nordisk, the maker of Ozempic, on March 5, 2026, alleging failure to adequately warn about severe gastrointestinal risks, including stomach paralysis.
“Novo Nordisk knew or should have known the risks posed by GLP-1 RA medications, including severe gastrointestinal complications and other injuries, but failed to update their warnings and labeling to adequately inform doctors and patients. They had a responsibility to disclose what they knew, and they didn’t,” Jonathan Orent, an attorney representing the Ettinghoff family, told Newsweek. []
Novo Nordiski disputes the claims and maintains confidence in the drug’s benefit-risk profile when used per labeling. []
Related: 5 unexpected side effects of Ozempic useWeight loss, at what cost?
GLP-1 receptor agonists—including semaglutide, tirzepatide, and liraglutide—achieve glycemic control and weight loss in part by slowing gastric emptying, prolonging satiety. []
That same mechanism underlies mounting concern:
Gastroparesis (delayed gastric emptying) has been cited in multiple lawsuits. []
Symptoms can include persistent nausea, vomiting, abdominal pain, and regurgitation. []
In severe cases, complications include aspiration, dehydration, and malnutrition. [] []
While common GI adverse effects are listed in the prescribing information, gastroparesis has historically been less prominently emphasized, though regulators have updated labels to include related risks such as ileus. []
Related: A woman had to remove a foot of her colon after taking OzempicSignal vs causation: What the data actually show
The Ettinghoff case emerges amid broader safety signals—but limited causal clarity:
FDA adverse event reporting data include dozens of deaths linked to GLP-1 agents; however, reporting does not establish causation. []
Observational analyses suggest increased risks of gastroparesis, bowel obstruction, and pancreatitis vs other weight-loss therapies. []
Clinically, diabetes itself is a major independent risk factor for gastroparesis, complicating attribution in many cases. []
What to tell patients concerned about gastroparesis on GLP-1s
For patients taking semaglutide or other GLP-1 receptor agonists, concern about “stomach paralysis” is increasingly common—and worth addressing directly with clear, practical guidance.
Start with context
Explain that delayed gastric emptying is an intended effect of these medications and helps with appetite control and glycemic response. Most patients experience mild, transient symptoms, typically early in treatment or after dose escalation.
Clarify what is expected vs concerning
Patients should understand the difference between common side effects and warning signs:
Common and often temporary
Mild nausea
Early fullness
Occasional vomiting during dose increases
Not typical—should prompt a call or visit
Persistent or worsening nausea beyond a few weeks
Repeated vomiting, especially of undigested food hours after eating
Inability to keep fluids down
Abdominal distention or pain that doesn’t resolve
Give concrete “stop and call” instructions
Patients benefit from specific thresholds rather than vague warnings:
“If you’re vomiting for more than a day or two, stop the medication and call us.”
“If food seems to sit in your stomach for hours or comes back up later, let us know.”
“If you feel weak, dizzy, or can’t stay hydrated, seek care urgently.”
Reinforce dose pacing and communication
Encourage patients not to rush dose escalation.
Normalize dose reduction or pauses if symptoms persist.
Let them know early reporting helps prevent complications.